Medically reviewed by John P. Cunha, DO, FACOEP; Board Certified Emergency Medicine

REFERENCES:

Bussing, R., D.M. Mason, L. Bell, P. Porter, and C. Garvan. “Adolescent outcomes of childhood attention-deficit/hyperactivity disorder in a diverse community sample.” Journal of the American Academy of Child and Adolescent Psychiatry 49.6 June 2010: 595-605.

De Sousa, A., and G. Kalra. “Drug therapy of attention deficit hyperactivity disorder: current trends.” Mens Sana Monographs 10.1 January-December 2012: 45-69.

Docherty, J.R. “Pharmacology of stimulants prohibited by the world anti-doping agency (WADA).” British Journal of Pharmacology 154.3 June 2008: 606-622.

Jernigan, M.G., G.M. Kipp, A. Rather, et al. “Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications.” Mental Health Clinics 2.9 (2013): 70.

Mao, K. “Can medical cannabis stop the ADHD epidemic?” Waking Times Apr. 11, 2013.

National Institute on Drug Abuse 1. “Drug facts: is marijuana medicine?” National Institute on Drug Abuse 2012 July.

National Institute on Drug Abuse 2. “Regular marijuana use by teens continues to be a concern.” National Institute on Drug Abuse 2012 December.

Physicians’ Desk Reference Network. Physicians’ Desk Reference, 67th ed. Montvale, New Jersey, 2013.

Roesch, B., M. Corcoran, M. Haffey, et al. “Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.” Drugs Research and Development 13.1 Mar. 2013: 53-61.

Wilens, T.E., N.R. Morrison, and J. Prince. “An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.” Expert Review in Neurotherapy 11.10 Oct. 2011: 1443-1465.